Combination therapy in metabolic dysfunction-associated steatohepatitis

The Lancet Gastroenterology & Hepatology · Published 2026-08-05 · DOI 10.1016/s2468-1253(26)00151-2

Authors (2)

Oren Shibolet, Helena Katchman

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Shibolet, O., Katchman, H. (2026). Combination therapy in metabolic dysfunction-associated steatohepatitis. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(26)00151-2

Related articles

• Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial · The Lancet Gastroenterology & Hepatology · 2026 · Cites or is cited by this article · Same journal
• Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial · The Lancet Gastroenterology & Hepatology · 2026 · Same journal
• Ethnicity, diversity, and inclusion in gastroenterology: from representation to system performance · The Lancet Gastroenterology & Hepatology · 2026 · Same journal
• Cyclic exclusive enteral nutrition in paediatric Crohn's disease – Authors’ reply · The Lancet Gastroenterology & Hepatology · 2026 · Same journal
• Rome V: refining the language of gut–brain disorders · The Lancet Gastroenterology & Hepatology · 2026 · Same journal
• The spectrum of steatotic liver disease in the USA – Authors’ reply · The Lancet Gastroenterology & Hepatology · 2026 · Same journal
• Drugging the undruggable in pancreatic cancer · The Lancet Gastroenterology & Hepatology · 2026 · Same journal
• Pathophysiology of irritable bowel syndrome · The Lancet Gastroenterology & Hepatology · 2026 · Same journal
• Translating the gut microbiome: where are we? · The Lancet Gastroenterology & Hepatology · 2026 · Same journal
• Therapeutic drift or formulation drift: avoiding misconceptions about rifaximin and antimicrobial resistance in cirrhosis · The Lancet Gastroenterology & Hepatology · 2026 · Same journal